Drugs / Gallium citrate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02776891 | Jun 2016 → Apr 2018 | Burkitt lymphoma, diffuse large B-cell lymphoma | University of California, San Francisco | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gallium citrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02776891 ↗ |
| Route | Intravenous | “It will be administered a single time point intravenously prior to PET imaging.” NCT02776891 ↗ |